Clopidogrel
Product Images NDC 53002-1672

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 53002-1672). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

The text is describing a figure that shows the exposure to Clopidogrel Active Metabolite after taking Clopidogrel Bisulfate 75mg alone or with Proton Pump Inhibitors (PPIs). The figure shows the effect of co-administered PPIs on the active metabolite AUC with the mean and 90% confidence interval. The figure compares the change relative to Clopidogrel Bisulfate alone, after taking Dexlansoprazole 60mg, Lansoprazole 30mg, Pantoprazole 80mg, and Omeprazole 80mg.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

This appears to be a table providing information on cardiovascular event rates for patients using either a placebo or Clopidogrel Bisulfate in conjunction with aspirin over the course of 12 months. The events tracked include cardiovascular death, myocardial infarction, and stroke. The data suggests that the combination of Clopidogrel Bisulfate and aspirin results in a significantly lower event rate than the placebo. The table also notes that other standard therapies were used in addition to the treatment being studied.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

This is a table showing data related to subgroups based on gender, age, medical history, and medication used. The data includes numbers and percentages of patients with specific medical conditions and the medications they were taking. There is also a section that shows the hazard ratio with a confidence interval. The text contains some errors and needs proofreading.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

The text describes a study comparing the mortality rate of a placebo group with a group treated with Clopidogrel. It shows that before the first discharge, 8.1% of the placebo group had died, whereas 7.5% of the group treated with Clopidogrel had died. This means that the Clopidogrel treatment led to a 7% reduction in the risk of death, with a p-value of 0.03. The graph represents the distribution of deaths across days since randomization, up to 28 days.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

This appears to be a table with information about a clinical trial involving two groups: Placebo and Clopidogrel. The table shows the number of participants in each group who had an event (10.1% for Placebo and 9.2% for Clopidogrel) as well as the proportional risk reduction for death, re-infarction or stroke (9% reduction for Clopidogrel). The table also shows a timeline ranging from 0 to 28 days since the start of the trial.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

This appears to be a graph displaying the cumulative event rate (in percentage) of fatal or non-fatal vascular events for patients taking either Aspirin or Clopidogrel Bisultate. The graph shows the follow-up period in months for up to 36 months.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

This appears to be a table or chart with data related to stroke, myocardial infarction (MI), peripheral artery disease (PAD), and the use of the medications clopidogrel and aspirin. The table lists the number of patients who qualified for the study (based on having one of the three conditions or an overall total), as well as the percentage of patients who were prescribed each medication. The chart appears to show a comparison of the outcomes of patients taking clopidogrel versus aspirin over a span of several years. Unfortunately, there is no text that explains the results or provides additional context, so it is unclear what the specific findings were.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

FDA Label Image

Label Image (Lbl530021672)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.